{"id":3942,"date":"2025-07-24T11:29:14","date_gmt":"2025-07-24T05:59:14","guid":{"rendered":"https:\/\/regisdigitals.com\/client\/Sunact\/?p=3942"},"modified":"2025-07-25T16:59:22","modified_gmt":"2025-07-25T11:29:22","slug":"tarlatamab-a-new-drug-shows-promise-for-difficult-to-treat-lung-cancer","status":"publish","type":"post","link":"https:\/\/regisdigitals.com\/client\/Sunact\/tarlatamab-a-new-drug-shows-promise-for-difficult-to-treat-lung-cancer\/","title":{"rendered":"Tarlatamab: A New Drug Shows Promise for Difficult to-Treat Lung Cancer"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3942\" class=\"elementor elementor-3942\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-db572db e-con-full e-flex e-con e-parent\" data-id=\"db572db\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-648c3b0 elementor-widget elementor-widget-text-editor\" data-id=\"648c3b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>24 July 2025<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6946a5a elementor-toc--minimized-on-tablet elementor-widget elementor-widget-table-of-contents\" data-id=\"6946a5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;headings_by_tags&quot;:[&quot;h3&quot;,&quot;h4&quot;],&quot;container&quot;:&quot;.elementor-widget-theme-post-content&quot;,&quot;no_headings_message&quot;:&quot;No headings were found on this page.&quot;,&quot;marker_view&quot;:&quot;numbers&quot;,&quot;minimize_box&quot;:&quot;yes&quot;,&quot;minimized_on&quot;:&quot;tablet&quot;,&quot;hierarchical_view&quot;:&quot;yes&quot;,&quot;min_height&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;min_height_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;min_height_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;min_height_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;min_height_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"table-of-contents.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-toc__header\">\n\t\t\t\t\t\t<h5 class=\"elementor-toc__header-title\">\n\t\t\t\tTable of Contents\t\t\t<\/h5>\n\t\t\t\t\t\t\t\t\t\t<div class=\"elementor-toc__toggle-button elementor-toc__toggle-button--expand\" role=\"button\" tabindex=\"0\" aria-controls=\"elementor-toc__6946a5a\" aria-expanded=\"true\" aria-label=\"Open table of contents\"><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg><\/div>\n\t\t\t\t<div class=\"elementor-toc__toggle-button elementor-toc__toggle-button--collapse\" role=\"button\" tabindex=\"0\" aria-controls=\"elementor-toc__6946a5a\" aria-expanded=\"true\" aria-label=\"Close table of contents\"><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-up\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M240.971 130.524l194.343 194.343c9.373 9.373 9.373 24.569 0 33.941l-22.667 22.667c-9.357 9.357-24.522 9.375-33.901.04L224 227.495 69.255 381.516c-9.379 9.335-24.544 9.317-33.901-.04l-22.667-22.667c-9.373-9.373-9.373-24.569 0-33.941L207.03 130.525c9.372-9.373 24.568-9.373 33.941-.001z\"><\/path><\/svg><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<div id=\"elementor-toc__6946a5a\" class=\"elementor-toc__body\">\n\t\t\t<div class=\"elementor-toc__spinner-container\">\n\t\t\t\t<svg class=\"elementor-toc__spinner eicon-animation-spin e-font-icon-svg e-eicon-loading\" aria-hidden=\"true\" viewBox=\"0 0 1000 1000\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M500 975V858C696 858 858 696 858 500S696 142 500 142 142 304 142 500H25C25 237 238 25 500 25S975 237 975 500 763 975 500 975Z\"><\/path><\/svg>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ae4b434 elementor-widget elementor-widget-heading\" data-id=\"ae4b434\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Introduction<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-43eb0b0 elementor-widget elementor-widget-text-editor\" data-id=\"43eb0b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Lung cancer is one of the deadliest cancers in the world, and small-cell lung cancer (SCLC) is\u00a0 its most aggressive form. It is difficult to treat and often comes back even after the treatment. A platinum-based chemotherapy called \u201cEtoposide\u201d is the first line of therapy given to the SCLC patients. Unfortunately, there are multiple patients who are resistant to\u00a0 this therapy and need another therapeutic regimen. Over the past 30 years, the second line\u00a0 therapy options for the treatment on SCLC have been limited where Topotecan is the sole standard of care treatment available in most of the countries. Now, there&#8217;s a new drug offering hope: Tarlatamab.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-750d293 elementor-widget elementor-widget-image\" data-id=\"750d293\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1131\" height=\"960\" src=\"https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/07\/Tarlatamab.webp\" class=\"attachment-full size-full wp-image-3966\" alt=\"Tarlatamab for lung cancer \u2013 innovative targeted therapy attacking cancer cells\" srcset=\"https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/07\/Tarlatamab.webp 1131w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/07\/Tarlatamab-300x255.webp 300w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/07\/Tarlatamab-1024x869.webp 1024w, https:\/\/regisdigitals.com\/client\/Sunact\/wp-content\/uploads\/2025\/07\/Tarlatamab-768x652.webp 768w\" sizes=\"(max-width: 1131px) 100vw, 1131px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f67903 elementor-widget elementor-widget-heading\" data-id=\"2f67903\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">What is Tarlatamab?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a02dd07 elementor-widget elementor-widget-text-editor\" data-id=\"a02dd07\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Tarlatamab is a new kind of medicine that helps the immune system find and destroy cancer cells. It targets a protein called DLL3, which is found mostly on small cell lung cancer cells but not on healthy cells. Tarlatamab works by acting like a bridge between immune cells (specifically T cells) and cancer cells and helps T cells to attaches to DLL3, which in turn recognize and kill the cancer cells.\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-90a8716 elementor-widget elementor-widget-heading\" data-id=\"90a8716\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">How Was the Study Done?\n<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1a609e6 elementor-widget elementor-widget-text-editor\" data-id=\"1a609e6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Doctors ran a clinical trial to test how well Tarlatamab works and how safe it is. They gave the drug to over 500 patients with SCLC who had already tried chemotherapy but whose cancer had returned. The medicine was given through an IV drip every two weeks, and doctors watched closely to see: 1. If tumors shrank or stopped growing 2. How long the effect lasted 3. What side effects patients had<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0f44170 elementor-widget elementor-widget-heading\" data-id=\"0f44170\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">What Did the Study Find?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d61d8c5 elementor-widget elementor-widget-text-editor\" data-id=\"d61d8c5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The results of this study were encouraging: 1. In almost 40% of patients responded to the treatment, meaning their tumors shrank or stopped growing for a period of time. 2. Some patients had long-lasting responses, with their cancer remaining under control for several months or more. 3. While there were some side effects (as with most cancer treatments), most of them were manageable. The most common were flu-like symptoms, fatigue, and low blood pressure.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7198f51 elementor-widget elementor-widget-heading\" data-id=\"7198f51\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">How Does It Compare to Chemotherapy?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2ef012f elementor-widget elementor-widget-text-editor\" data-id=\"2ef012f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">Chemotherapy is often the first treatment for SCLC and can work well at first. However, it attacks both cancer and healthy cells, leading to common side effects like hair loss, nausea, and low blood counts. When the cancer returns after chemotherapy, response rates to second-line chemo are usually below 25% and often short-lived. Tarlatamab, on the other hand, offers a more targeted approach, helping the immune system attack only the cancer cells. In this study, response rates were higher than typical second-line chemotherapy, and side effects were generally milder and more specific.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f3e70d5 elementor-widget elementor-widget-heading\" data-id=\"f3e70d5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Why Is This Important?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9cf59f6 elementor-widget elementor-widget-text-editor\" data-id=\"9cf59f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">For decades, treatment for small-cell lung cancer hasn\u2019t changed much and the survival rates have remained low. A few of immunotherapy were successful in some patients, but the success rate is very low. Tarlatamab brings a new approach by combining the power of the immune system with precision targeting of cancer-specific markers. That\u2019s a big step forward in a field where every bit of progress counts.\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bd09f9a elementor-widget elementor-widget-heading\" data-id=\"bd09f9a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Takeaway<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41b4dec elementor-widget elementor-widget-text-editor\" data-id=\"41b4dec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">For people with relapsed SCLC, treatment choices are limited and often not very effective. Tarlatamab is a new kind of treatment that could change that. While more research is needed, it offers real hope for longer-lasting results with fewer side effects compared to traditional chemotherapy<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-68a4de2 elementor-widget elementor-widget-heading\" data-id=\"68a4de2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">-\u00a0Medically reviewed by Dr. Prerna Chaudhary (Lead Scientist) at SunAct - Advanced Cancer Therapies.\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>24 July 2025 Table of Contents Introduction Lung cancer is one of the deadliest cancers in the world, and small-cell lung cancer (SCLC) is\u00a0 its most aggressive form. It is difficult to treat and often comes back even after the treatment. A platinum-based chemotherapy called \u201cEtoposide\u201d is the first line of therapy given to the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3966,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3942","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/posts\/3942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/comments?post=3942"}],"version-history":[{"count":0,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/posts\/3942\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/media\/3966"}],"wp:attachment":[{"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/media?parent=3942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/categories?post=3942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regisdigitals.com\/client\/Sunact\/wp-json\/wp\/v2\/tags?post=3942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}